钠-葡萄糖共转运体-2 抑制剂对 2 型糖尿病患者卵巢癌风险的影响：一项多机构 TriNetX 研究。

IF 6.1 3区医学 Q1 ENDOCRINOLOGY & METABOLISM

Diabetes research and clinical practice Pub Date : 2025-03-18 DOI:10.1016/j.diabres.2025.112109

Cheng-Hsien Hung , Jheng-Yan Wu , Yueh-Shan Weng , Li-Wei Hsiao , Yu-Chang Liu , I-Tsang Chiang

{"title":"钠-葡萄糖共转运体-2 抑制剂对 2 型糖尿病患者卵巢癌风险的影响：一项多机构 TriNetX 研究。","authors":"Cheng-Hsien Hung , Jheng-Yan Wu , Yueh-Shan Weng , Li-Wei Hsiao , Yu-Chang Liu , I-Tsang Chiang","doi":"10.1016/j.diabres.2025.112109","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Women with type 2 diabetes mellitus (T2DM) have an increased risk of ovarian cancer. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) impact on the risk of ovarian cancer in women with T2DM remains unclear. Therefore, this study aims to assess the association between SGLT2i use and the risk of ovarian cancer in patients with T2DM.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using the TriNetX network between January 2013 and December 2023. We employed a new-user study design with an active comparator, comparing patients using dipeptidyl peptidase-4 inhibitors (DPP4i). Propensity score matching (PSM) was applied to balance baseline characteristics. The primary outcome was the incidence of ovarian cancer.</div></div><div><h3>Results</h3><div>Following PSM, 92,090 patients were included in each group. The SGLT2i gorup was associated with a significantly lower risk of ovarian cancer compared to the DPP4i group (HR: 0.758, 95 % CI: 0.596–0.965). Subgroup analyses revealed a consistent trend across various populations, with a notably significant risk reduction observed in white patients (HR: 0.667, 95 % CI: 0.485–0.917).</div></div><div><h3>Conclusions</h3><div>Our study suggests that SGLT2i may be associated with lower risk of ovarian cancer in T2DM patients. These findings highlight the need for further investigation into the underlying mechanisms.</div></div>","PeriodicalId":11249,"journal":{"name":"Diabetes research and clinical practice","volume":"222 ","pages":"Article 112109"},"PeriodicalIF":6.1000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Impact of sodium-glucose cotransporter-2 inhibitors on ovarian cancer risk in patients with type 2 diabetes mellitus: A multi-institutional TriNetX study\",\"authors\":\"Cheng-Hsien Hung , Jheng-Yan Wu , Yueh-Shan Weng , Li-Wei Hsiao , Yu-Chang Liu , I-Tsang Chiang\",\"doi\":\"10.1016/j.diabres.2025.112109\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><div>Women with type 2 diabetes mellitus (T2DM) have an increased risk of ovarian cancer. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) impact on the risk of ovarian cancer in women with T2DM remains unclear. Therefore, this study aims to assess the association between SGLT2i use and the risk of ovarian cancer in patients with T2DM.</div></div><div><h3>Methods</h3><div>We conducted a retrospective cohort study using the TriNetX network between January 2013 and December 2023. We employed a new-user study design with an active comparator, comparing patients using dipeptidyl peptidase-4 inhibitors (DPP4i). Propensity score matching (PSM) was applied to balance baseline characteristics. The primary outcome was the incidence of ovarian cancer.</div></div><div><h3>Results</h3><div>Following PSM, 92,090 patients were included in each group. The SGLT2i gorup was associated with a significantly lower risk of ovarian cancer compared to the DPP4i group (HR: 0.758, 95 % CI: 0.596–0.965). Subgroup analyses revealed a consistent trend across various populations, with a notably significant risk reduction observed in white patients (HR: 0.667, 95 % CI: 0.485–0.917).</div></div><div><h3>Conclusions</h3><div>Our study suggests that SGLT2i may be associated with lower risk of ovarian cancer in T2DM patients. These findings highlight the need for further investigation into the underlying mechanisms.</div></div>\",\"PeriodicalId\":11249,\"journal\":{\"name\":\"Diabetes research and clinical practice\",\"volume\":\"222 \",\"pages\":\"Article 112109\"},\"PeriodicalIF\":6.1000,\"publicationDate\":\"2025-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes research and clinical practice\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0168822725001238\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes research and clinical practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0168822725001238","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

摘要

简介患有 2 型糖尿病（T2DM）的女性罹患卵巢癌的风险会增加。钠-葡萄糖共转运体 2 抑制剂（SGLT2i）对 2 型糖尿病妇女罹患卵巢癌风险的影响尚不清楚。因此，本研究旨在评估 T2DM 患者使用 SGLT2i 与卵巢癌风险之间的关联：我们利用 TriNetX 网络开展了一项回顾性队列研究，研究时间为 2013 年 1 月至 2023 年 12 月。我们采用了一项新用户研究设计，并将使用二肽基肽酶-4 抑制剂（DPP4i）的患者作为主动比较对象。采用倾向评分匹配（PSM）平衡基线特征。主要结果是卵巢癌的发病率：经过倾向评分匹配，每组共纳入 92090 名患者。与 DPP4i 组相比，SGLT2i gorup 与卵巢癌风险显著降低相关（HR：0.758，95 % CI：0.596-0.965）。亚组分析显示，不同人群的趋势一致，白人患者的风险明显降低（HR：0.667，95 % CI：0.485-0.917）：我们的研究表明，SGLT2i 可能与降低 T2DM 患者罹患卵巢癌的风险有关。这些发现强调了进一步研究其潜在机制的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Impact of sodium-glucose cotransporter-2 inhibitors on ovarian cancer risk in patients with type 2 diabetes mellitus: A multi-institutional TriNetX study

Introduction

Women with type 2 diabetes mellitus (T2DM) have an increased risk of ovarian cancer. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) impact on the risk of ovarian cancer in women with T2DM remains unclear. Therefore, this study aims to assess the association between SGLT2i use and the risk of ovarian cancer in patients with T2DM.

Methods

We conducted a retrospective cohort study using the TriNetX network between January 2013 and December 2023. We employed a new-user study design with an active comparator, comparing patients using dipeptidyl peptidase-4 inhibitors (DPP4i). Propensity score matching (PSM) was applied to balance baseline characteristics. The primary outcome was the incidence of ovarian cancer.

Results

Following PSM, 92,090 patients were included in each group. The SGLT2i gorup was associated with a significantly lower risk of ovarian cancer compared to the DPP4i group (HR: 0.758, 95 % CI: 0.596–0.965). Subgroup analyses revealed a consistent trend across various populations, with a notably significant risk reduction observed in white patients (HR: 0.667, 95 % CI: 0.485–0.917).

Conclusions

Our study suggests that SGLT2i may be associated with lower risk of ovarian cancer in T2DM patients. These findings highlight the need for further investigation into the underlying mechanisms.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Diabetes research and clinical practice 医学-内分泌学与代谢

CiteScore

10.30

自引率

3.90%

发文量

862

审稿时长

32 days

期刊介绍： Diabetes Research and Clinical Practice is an international journal for health-care providers and clinically oriented researchers that publishes high-quality original research articles and expert reviews in diabetes and related areas. The role of the journal is to provide a venue for dissemination of knowledge and discussion of topics related to diabetes clinical research and patient care. Topics of focus include translational science, genetics, immunology, nutrition, psychosocial research, epidemiology, prevention, socio-economic research, complications, new treatments, technologies and therapy.